These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 15712395)

  • 1. The impact of abacavir on lipids and lipodystrophy.
    Moyle GJ
    AIDS Read; 2005 Feb; 15(2):62-6. PubMed ID: 15712395
    [No Abstract]   [Full Text] [Related]  

  • 2. Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backbone.
    Moyle GJ
    AIDS Read; 2003 Nov; 13(11):528, 533-5. PubMed ID: 14649622
    [No Abstract]   [Full Text] [Related]  

  • 3. Abacavir and lamivudine combination.
    Somboonwit C; Kurtyka D; Velez AP
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1599-606. PubMed ID: 19929448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abacavir/lamivudine/zidovudine continues to be a valid and useful antiretroviral regimen.
    Shaefer MS
    Ann Pharmacother; 2004; 38(7-8):1314-6. PubMed ID: 15187204
    [No Abstract]   [Full Text] [Related]  

  • 5. Abacavir: new preparation. Risks limit the value.
    Prescrire Int; 2000 Jun; 9(47):67-9. PubMed ID: 11010740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abacavir arm stopped in clinical trial.
    James JS
    AIDS Treat News; 2003 Apr; (390):6-7. PubMed ID: 12739475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
    Kuritzkes DR
    J Infect Dis; 2005 Dec; 192(11):1867-8. PubMed ID: 16267755
    [No Abstract]   [Full Text] [Related]  

  • 8. Incidence of abacavir hypersensitivity reactions in euroSIDA.
    Bannister WP; Friis-Møller N; Mocroft A; Viard JP; van Lunzen J; Kirk O; Gargalianos P; Bánhegyi D; Chiesi A; Lundgren JD;
    Antivir Ther; 2008; 13(5):687-96. PubMed ID: 18771052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AIDS and lipodystrophy: complications of HIV and HIV treatments.
    Laurence J
    AIDS Patient Care STDS; 1999 Jul; 13(7):389-90. PubMed ID: 10870591
    [No Abstract]   [Full Text] [Related]  

  • 10. Coming therapies: abacavir.
    Staszewski S
    Int J Clin Pract Suppl; 1999 Jun; 103():35-8. PubMed ID: 10622042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-HIV agents. Abacavir--as good as AZT?
    TreatmentUpdate; 2003 Oct; 15(6):3-4. PubMed ID: 17216861
    [No Abstract]   [Full Text] [Related]  

  • 12. Factors influencing the development of lipodystrophy in human immunodeficiency virus-infected patients.
    Collazos J; Rodriguez-Guardado A; Maradona JA; Mayo J; Asensi V; Ibarra S; Carton JA; Casado L
    Scand J Infect Dis; 2003; 35(5):339-40. PubMed ID: 12875524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA notifications. Tentative approval for fixed-dose combo abacavir/lamivudine.
    AIDS Alert; 2009 Feb; 24(2):22. PubMed ID: 19219952
    [No Abstract]   [Full Text] [Related]  

  • 14. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment.
    Kirkland LR; Fischl MA; Tashima KT; Paar D; Gensler T; Graham NM; Gao H; Rosenzweig JR; McClernon DR; Pittman G; Hessenthaler SM; Hernandez JE;
    Clin Infect Dis; 2002 Feb; 34(4):511-8. PubMed ID: 11797179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy.
    Maitland D; Jackson A; Osorio J; Mandalia S; Gazzard BG; Moyle GJ;
    HIV Med; 2008 Oct; 9(8):667-72. PubMed ID: 18631255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.
    Rozenbaum W; Katlama C; Massip P; Bentata M; Zucman D; Delfraissy JF; Trepo C; David F; Lanier ER; Vavro C; Mamet JP
    Antivir Ther; 2001 Jun; 6(2):135-42. PubMed ID: 11491418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
    J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA notifications. Tentative approval given for combination of abacavir, lamivudine & zidovudine tablets.
    AIDS Alert; 2009 Sep; 24(9):106. PubMed ID: 19928326
    [No Abstract]   [Full Text] [Related]  

  • 19. Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study.
    Cohen CJ; Kubota M; Brachman PS; Harley WB; Schneider S; Williams VC; Sutherland-Phillips DH; Lim ML; Balu RB; Shaefer MS;
    Pharmacotherapy; 2008 Mar; 28(3):314-22. PubMed ID: 18294111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sweet's syndrome following abacavir therapy.
    Del Giudice P; Vandenbos F; Perrin C; Bernard E; Marq L; Dellamonica P
    J Am Acad Dermatol; 2004 Sep; 51(3):474-5. PubMed ID: 15337997
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.